EQUILLIUM, INC. Deferred Income Tax Expense (Benefit)
EQUILLIUM, INC. (EQ) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2024-03-25
- EQUILLIUM, INC. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
- EQUILLIUM, INC. deferred income tax expense (benefit) for fiscal 2021 was $0.00.
- EQUILLIUM, INC. deferred income tax expense (benefit) for fiscal 2020 was $0.00.
- EQUILLIUM, INC. deferred income tax expense (benefit) for fiscal 2019 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2024-03-25 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-23 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-24 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |